A citation-based method for searching scientific literature

Michael S Leapman, Peter R Carroll. Urol Oncol 2017
Times Cited: 9







List of co-cited articles
6 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Freddie C Hamdy, Jenny L Donovan, J Athene Lane, Malcolm Mason, Chris Metcalfe, Peter Holding, Michael Davis, Tim J Peters, Emma L Turner, Richard M Martin,[...]. N Engl J Med 2016
22


Recent progress and perspectives on prostate cancer biomarkers.
Shingo Hatakeyama, Tohru Yoneyama, Yuki Tobisawa, Chikara Ohyama. Int J Clin Oncol 2017
36
22

Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.
Leonard P Bokhorst, Inari Lepistö, Yoshiyuki Kakehi, Chris H Bangma, Tom Pickles, Riccardo Valdagni, Arnout R Alberts, Axel Semjonow, Petra Strölin, Manuel F Montesino,[...]. BJU Int 2016
28
22

Contemporary evaluation of the D'amico risk classification of prostate cancer.
David J Hernandez, Matthew E Nielsen, Misop Han, Alan W Partin. Urology 2007
71
22

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
J L Donovan, F C Hamdy, J A Lane, M Mason, C Metcalfe, E Walsh, J M Blazeby, T J Peters, P Holding, S Bonnington,[...]. N Engl J Med 2016
515
11

What is the best way to radiate the prostate in 2016?
Dominic H Moon, Jason A Efstathiou, Ronald C Chen. Urol Oncol 2017
21
11

Accuracy of marketing claims by providers of stereotactic radiation therapy.
Amol K Narang, Edwin Lam, Martin A Makary, Theodore L Deweese, Timothy M Pawlik, Peter J Pronovost, Joseph M Herman. J Oncol Pract 2013
10
11

Predicting 15-year prostate cancer specific mortality after radical prostatectomy.
Scott E Eggener, Peter T Scardino, Patrick C Walsh, Misop Han, Alan W Partin, Bruce J Trock, Zhaoyong Feng, David P Wood, James A Eastham, Ofer Yossepowitch,[...]. J Urol 2011
410
11


Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
Ronald C Chen, R Bryan Rumble, D Andrew Loblaw, Antonio Finelli, Behfar Ehdaie, Matthew R Cooperberg, Scott C Morgan, Scott Tyldesley, John J Haluschak, Winston Tan,[...]. J Clin Oncol 2016
175
11


Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.
Danni L Meany, Zhen Zhang, Lori J Sokoll, Hui Zhang, Daniel W Chan. J Proteome Res 2009
94
11

Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
J Morote, A Celma, J Planas, J Placer, R Ferrer, I de Torres, R Pacciuci, M Olivan. Actas Urol Esp 2016
6
16


Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
Joan C Vilanova, Carles Barceló-Vidal, Josep Comet, Maria Boada, Joaquim Barceló, Joana Ferrer, Joan Albanell. AJR Am J Roentgenol 2011
52
11

Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum.
Jonathan E Shoag, Peter N Schlegel, Jim C Hu. J Clin Oncol 2016
5
20

The Prostate Health Index: a new test for the detection of prostate cancer.
Stacy Loeb, William J Catalona. Ther Adv Urol 2014
74
11


Modernizing the diagnostic and decision-making pathway for prostate cancer.
Thomas J Polascik, Niccolo' M Passoni, Arnauld Villers, Peter L Choyke. Clin Cancer Res 2014
15
11


Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
Carsten Stephan, Sébastien Vincendeau, Alain Houlgatte, Henning Cammann, Klaus Jung, Axel Semjonow. Clin Chem 2013
77
11

Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.
Qing Kay Li, Li Chen, Ming-Hui Ao, Joyce Hanching Chiu, Zhen Zhang, Hui Zhang, Daniel W Chan. Theranostics 2015
38
11

Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
Rosa Peracaula, Glòria Tabarés, Louise Royle, David J Harvey, Raymond A Dwek, Pauline M Rudd, Rafael de Llorens. Glycobiology 2003
185
11

Screening: Diagnostic dilemma.
Emily Sohn. Nature 2015
13
11

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.
Esther Llop, Montserrat Ferrer-Batallé, Sílvia Barrabés, Pedro Enrique Guerrero, Manel Ramírez, Radka Saldova, Pauline M Rudd, Rosa N Aleixandre, Josep Comet, Rafael de Llorens,[...]. Theranostics 2016
63
11

Biomarkers in prostate cancer: what's new?
David A Sartori, Daniel W Chan. Curr Opin Oncol 2014
86
11

The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Marianne Schmid, Quoc-Dien Trinh, Markus Graefen, Margit Fisch, Felix K Chun, Jens Hansen. World J Urol 2014
5
20

Glycan characterization of PSA 2-DE subforms from serum and seminal plasma.
Ariadna Sarrats, Radka Saldova, Josep Comet, Niaobh O'Donoghue, Rafael de Llorens, Pauline M Rudd, Rosa Peracaula. OMICS 2010
46
11

Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.
Wenying Wang, Meilin Wang, Li Wang, Tamara S Adams, Ye Tian, Jianfeng Xu. Sci Rep 2014
47
11

Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study.
Massimo Lazzeri, Giovanni Lughezzani, Alexander Haese, Thomas McNicholas, Alexandre de la Taille, Nicolò Maria Buffi, Pasquale Cardone, Rodolfo Hurle, Paolo Casale, Vittorio Bini,[...]. Urol Oncol 2016
14
11

[-2]proPSA is an early marker for prostate cancer aggressiveness.
I Heidegger, H Klocker, E Steiner, V Skradski, M Ladurner, R Pichler, G Schäfer, W Horninger, J Bektic. Prostate Cancer Prostatic Dis 2014
20
11


Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Glòria Tabarés, Catherine M Radcliffe, Sílvia Barrabés, Manel Ramírez, R Núria Aleixandre, Wolfgang Hoesel, Raymond A Dwek, Pauline M Rudd, Rosa Peracaula, Rafael de Llorens. Glycobiology 2006
114
11


Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Ariadna Sarrats, Josep Comet, Glòria Tabarés, Manel Ramírez, R Núria Aleixandre, Rafael de Llorens, Rosa Peracaula. Prostate 2010
31
11

An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
Tomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Tatsuo Kurosawa, Kenji Nakamura, Shintaro Narita, Koji Mitsuzuka, Wilhelmina Duivenvoorden, Jehonathan H Pinthus,[...]. Int J Mol Sci 2017
17
11

Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
Chikara Ohyama, Masahiro Hosono, Kazuo Nitta, Masayoshi Oh-eda, Kazuyuki Yoshikawa, Tomonori Habuchi, Yoichi Arai, Minoru Fukuda. Glycobiology 2004
100
11

Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.
Tohru Yoneyama, Chikara Ohyama, Shingo Hatakeyama, Shintaro Narita, Tomonori Habuchi, Takuya Koie, Kazuyuki Mori, Kazuya I P J Hidari, Maho Yamaguchi, Takashi Suzuki,[...]. Biochem Biophys Res Commun 2014
44
11

Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Carsten Stephan, Hellmuth-Alexander Meyer, Eva-Maria Paul, Glen Kristiansen, Stefan A Loening, Michael Lein, Klaus Jung. Anticancer Res 2007
12
11


A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
S D Mikolajczyk, L S Millar, T J Wang, H G Rittenhouse, L S Marks, W Song, T M Wheeler, K M Slawin. Cancer Res 2000
101
11

Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer.
Nitin K Yerram, Dmitry Volkin, Baris Turkbey, Jeffrey Nix, Anthony N Hoang, Srinivas Vourganti, Gopal N Gupta, W Marston Linehan, Peter L Choyke, Bradford J Wood,[...]. BJU Int 2012
75
11

An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up.
Matthew D Truesdale, Philippa J Cheetham, Gregory W Hruby, Sven Wenske, Alison K Conforto, Amy B Cooper, Aaron E Katz. Cancer J 2010
62
11

Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.
Akhil Muthigi, Abhinav Sidana, Arvin K George, Michael Kongnyuy, Nabeel Shakir, Meet Kadakia, Mahir Maruf, Thomas P Frye, Francesca Mertan, Daniel Su,[...]. Int Urol Nephrol 2016
8
12


Risk stratification of prostate cancer: integrating multiparametric MRI, nomograms and biomarkers.
Matthew J Watson, Arvin K George, Mahir Maruf, Thomas P Frye, Akhil Muthigi, Michael Kongnyuy, Subin G Valayil, Peter A Pinto. Future Oncol 2016
14
11

Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
Amir Toussi, Suzanne B Stewart-Merrill, Stephen A Boorjian, Sarah P Psutka, R Houston Thompson, Igor Frank, Matthew K Tollefson, Matthew T Gettman, Rachel E Carlson, Laureano J Rangel,[...]. J Urol 2016
27
11

Cryosurgery, an alternative treatment option for organ-confined prostate cancer: current beliefs and practice patterns of urologists.
Michael Kongnyuy, Daniel M Halpern, Kaitlin E Kosinski, Aaron E Katz. Int Urol Nephrol 2017
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.